Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01960218
Other study ID # 0512
Secondary ID
Status Recruiting
Phase N/A
First received October 4, 2013
Last updated April 3, 2014
Start date October 2013
Est. completion date January 2015

Study information

Verified date April 2014
Source Shape Medical Systems, Inc.
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Observational

Clinical Trial Summary

To determine whether, and if so, which gas exchange parameters measured on the Shape-HF Cardiopulmonary Exercise Testing System predict 30 and 180 day re-hospitalization in subjects discharged from hospitalization for an episode of acute decompensated heart failure.


Description:

This is a prospective, single-specialty clinical study. This study is intended to evaluate the select gas exchange parameters during a short, sub-max bout of exercise using a simple stationary step on day of discharge to predict the subjects' readmission for acute decompensated heart failure.


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date January 2015
Est. primary completion date July 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Subject is 18 Years and older

- Subject is hospitalized for acute decompensated heart failure (ADHF)

1. Systolic OR

2. Diastolic

- Subject is Stage C:Class II/III/IV heart failure

- Subject is willing and to provide appropriate informed consent

- Subject is willing and able to comply with the requirements of the protocol, including follow-up evaluations and schedule

- Subject is willing to use the Shape-HF Cardiopulmonary Exercise Testing System

Exclusion Criteria:

- The subject is pregnant (verified in a manner consistent with institution's standard of care)

- Subject is currently participating in another investigational device or drug trial

- Subject is a prisoner, a minor or unable to adequately give informed consent due to mental or physical condition

- Subject is unwilling or unable to return for the required follow-up after test

- Subject has Left Ventricular Assist Device (LVAD)

- Subject is listed for transplant

- Subject has a clinical diagnosis of acute myocardial infarction (AMI) on admission (Note: If troponin measurements have been collected and are elevated but not due to an MI subject is still eligible for study)

- Subject has a pulmonary embolism (PE) on admission

- Subject is dialysis dependent

- Subject has a cardiac resynchronization device (CRT) which has been re-programmed at any time during the study

- Subject has Chronic Obstructive Pulmonary Disease (COPD) who is oxygen or steroid dependent

- Subject has severe hypertension > 180 millimeter of mercury (mmHg) resting systolic at time of test

- Subject has severe heart failure with renal insufficiency (with Creatinine clearance rate (CrCL) of 30 or less) and/or on IV Inotropic therapy and/or enrolling in hospice

Study Design

Observational Model: Case-Only, Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
United States Massachusetts General Hospital Boston Massachusetts
United States Christie Clinic Champaign Illinois
United States Cleveland Clinic Cleveland Ohio
United States Fairview Southdale Edina Minnesota
United States University of Minnesota Minneapolis Minnesota
United States Washington University of Medicine St. Louis Missouri
United States Veterans Affairs-Washington DC Washington District of Columbia

Sponsors (1)

Lead Sponsor Collaborator
Shape Medical Systems, Inc.

Country where clinical trial is conducted

United States, 

References & Publications (4)

Fang J, Mensah GA, Croft JB, Keenan NL. Heart failure-related hospitalization in the U.S., 1979 to 2004. J Am Coll Cardiol. 2008 Aug 5;52(6):428-34. doi: 10.1016/j.jacc.2008.03.061. — View Citation

Jacobs B. Reducing heart failure hospital readmissions from skilled nursing facilities. Prof Case Manag. 2011 Jan-Feb;16(1):18-24; quiz 25-6. doi: 10.1097/NCM.0b013e3181f3f684. — View Citation

Pulignano G, Del Sindaco D, Tavazzi L, Lucci D, Gorini M, Leggio F, Porcu M, Scherillo M, Opasich C, Di Lenarda A, Senni M, Maggioni AP; IN-CHF Investigators. Clinical features and outcomes of elderly outpatients with heart failure followed up in hospital cardiology units: data from a large nationwide cardiology database (IN-CHF Registry). Am Heart J. 2002 Jan;143(1):45-55. — View Citation

Yu CM, Wang L, Chau E, Chan RH, Kong SL, Tang MO, Christensen J, Stadler RW, Lau CP. Intrathoracic impedance monitoring in patients with heart failure: correlation with fluid status and feasibility of early warning preceding hospitalization. Circulation. 2005 Aug 9;112(6):841-8. Epub 2005 Aug 1. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary 1. To evaluate if exercise gas exchange tests can predict 30 day hospital readmission for heart failure. The analysis of exercise gas exchange (using the Shape-HF Cardiopulmonary Exercise Testing System) of the incidence of hospital readmission through 30 days ± 3 days post discharge follow-up. 30 days ± 3 days post discharge No
Primary 2. To evaluate which gas exchange patterns were most highly associated with 30 day risk of readmission for recurrent acute decompensated heart failure. The analysis of exercise gas exchange (using the Shape-HF Cardiopulmonary Exercise Testing System) of the incidence of hospital readmission through 30 days ± 3 days post discharge follow-up. 30 days ± 3 days post discharge No
Primary 3. To determine the incidence of Adverse Events (AE) and Serious Adverse Events (SAE). The analysis of the incidence of AEs and SAEs on the day of discharge post Shape-HF Cardiopulmonary Exercise Testing System through 30 days ± 3 days post discharge follow-up and through 180 days ± 15 days post discharge follow-up. 30 days ± 3 days post discharge follow-up and through 180 days ± 15 days post discharge No
Secondary 1. To evaluate if exercise gas exchange tests can predict 180 day hospital readmission for heart failure. The analysis of exercise gas exchange (using the Shape-HF Cardiopulmonary Exercise Testing System) of the incidence of hospital readmission through 180 days ± 15 days post discharge follow-up. 180 days ± 15 days post discharge No
Secondary 2. To evaluate which gas exchange patterns were most highly associated with 180 day risk of readmission for recurrent acute decompensated heart failure. The analysis of exercise gas exchange (using the Shape-HF Cardiopulmonary Exercise Testing System) of the incidence of hospital readmission through 180 days ± 15 days post discharge follow-up. 180 days ± 15 days post discharge No
See also
  Status Clinical Trial Phase
Completed NCT04049045 - Effects of Empagliflozin on Diuresis and Renal Function in Patients With Acute Decompensated Heart Failure Phase 2
Active, not recruiting NCT05100836 - SURPASS Impella 5.5 Study
Recruiting NCT02898181 - Low Level Tragus Stimulation in Acute Decompensated Heart Failure N/A
Completed NCT02823626 - High-dose Aldosterone Antagonist for Acute Decompensated Heart Failure
Completed NCT02196038 - A Trial of Rehabilitation Therapy in Older Acute Heart Failure Patients N/A
Completed NCT02248831 - Evaluation of Cardiopulmonary Diseases by Ultrasound N/A
Completed NCT00693745 - Neutrophil Gelatinase-Associated Lipcalin (NGAL) Evaluation Along With B-Type Natriuretic Peptide in Acutely Decompensated HF N/A
Not yet recruiting NCT04391231 - HEMolysis in a Percutaneous Axial Flow LVAD, Effects of Pentoxifylline in a Randomized Controlled Trial Phase 4
Recruiting NCT05206422 - DORAYA-HF Early Feasibility Study N/A
Terminated NCT00904488 - Oral Metolazone and Intermittent Intravenous Furosemide Versus Continuous Infusion Furosemide in Acute Heart Failure Phase 4
Terminated NCT02620384 - Metolazone As Early Add On Therapy For Acute Decompensated Heart Failure (MELT-HF)--A Single Center Pilot Study. Phase 3
Completed NCT04318093 - Study of the Safety of BMS-986259 in Participants With Post-Acute Decompensated Heart Failure Phase 2
Recruiting NCT06161649 - Mobile Education System to Improve Disease Knowledge, Self-efficacy and Quality of Life in Patients With Heart Failure N/A
Completed NCT02289508 - Role of USCOM in Adult Patients With Heart Failure N/A
Terminated NCT01457053 - Assessment of Coronary Flow Reserve in Heart Failure Patients After Ultrafiltration Versus Diuretics N/A
Completed NCT04877652 - DR REGISTRY: Prospective Observational Study of ADHF Patients With Insufficient Response to Diuretics
Completed NCT03505788 - Acetazolamide in Decompensated Heart Failure With Volume OveRload (ADVOR) Phase 4
Completed NCT03146754 - A Study to Evaluate Lung Ultrasound as a Method to Measure Changes in Extravascular Lung Water Induced by Positional Changes (LUPE) N/A
Not yet recruiting NCT06414759 - Efficacy and Safety of Combination Diuretic Therapy in Patients With Acute Decompensated Heart Failure and Volume Overload Phase 4
Terminated NCT05346653 - The Hemodynamic Effects of SGLT2i in Acute Decompensated Heart Failure Phase 4